Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 99   

Articles published

LGND 50.85 +0.42 (0.83%)
price chart
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Related articles »  
Ligand Pharmaceuticals Inc. (LGND) Largest Owner Sells Shares
Raising prospects for a continued deterioration in the stock price of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), the largest shareholder in the company has moved to unload shares of the troubled company in a private transactions.
Related articles »  
Ligand Licenses Captisol-enabled� Lamotrigine to CURx Pharmaceuticals, Inc.
SAN DIEGO, Sep 09, 2014 (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated LGND, +0.83% announced it has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of ...
Ligand, CURx expand accord  San Diego Source (subscription)
Related articles »  
Ligand Pharmaceuticals Stock Rating Upgraded by Zacks (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by Zacks from an �underperform� rating to a �neutral� rating in a research report issued on Friday.
Zacks Upgrades Ligand Pharmaceuticals to Neutral (LGND)
Ligand Pharmaceuticals Inc. logo Zacks upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND) from an underperform rating to a neutral rating in a research note released on Friday morning.
Related articles »  
Ligand Pharmaceuticals Upgraded to Neutral at Zacks (LGND)
Ligand Pharmaceuticals (NASDAQ:LGND) traded down 3.19% on Friday, hitting $51.31. 95,375 shares of the company's stock traded hands. Ligand Pharmaceuticals has a 52 week low of $39.75 and a 52 week high of $80.42. The stock's 50-day moving ...
Ligand Pharmaceuticals Upgraded to "Neutral" by Zacks (LGND)  Watch List News (press release)
Investors Alert : The Gap (NYSE:GPS), Baidu Inc (ADR) (NASDAQ:BIDU), Ligand ...  Tech News
Related articles »  
Ligand Pharmaceuticals CEO John L. Higgins Acquires 1000 Shares (LGND)
Ligand Pharmaceuticals has a 52-week low of $39.75 and a 52-week high of $80.42. The stock's 50-day moving average is $55.64 and its 200-day moving average is $64.17.
Ligand Pharma Inks Deal With Avion To Develop Captisol-enabled Programs  NASDAQ
Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance ...  CNNMoney
Related articles »  
Today's Hot List: 22nd Century Group, Inc. (NYSEMKT:XXII), Ligand ...
During the same quarter in the previous year, the company posted $0.07 earnings per share. The company's revenue for the quarter was up 10.4% on a year-over-year basis.
Related articles »  
Ligand Pharmaceuticals CEO Buys $54970 in Stock (LGND)
Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.14 by $0.10.
Stock Highlights: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ...  Crazy Joys
Insider Buying: Ligand Pharmaceuticals CEO John L. Higgins Buys 1000 Shares ...  WKRB News
Related articles »  
Lemelson Capital Comments on Ligand Pharmaceuticals (LGND) Going ...
Lemelson Capital Management, a private investment management firm, today released additional research and comments on Ligand Pharmaceuticals (NASDAQ: LGND) amidst the company's unusual and complex debt arrangement under which the firm has ...